第四版儿童ALL诊疗建议对HD-MTX肾毒性及血药浓度的影响
结果示新方案组低危和中危患儿AKI发生率更低、48小时MTX血药浓度及降至安全范围天数更短,但高危患儿两组间无显著差异。
要点
- 新方案组低危患儿AKI发生率1.3%(3/229),低于原方案组7.9%(24/303)。
- 新方案组中危患儿AKI发生率4.9%(10/204),低于原方案组12.8%(26/203)。
- 高危患儿两组AKI发生率及MTX血药浓度差异均无统计学意义,需密切监测。
核心结论
- 按第四次修订方案行HD-MTX化疗后,低危和中危ALL患儿肾毒性发生风险降低且MTX体内清除时间缩短。
- 高危患儿两种方案间肾毒性及MTX血药浓度无明显变化,应注意密切监测。
研究设计与样本
- 按化疗方案分为原方案组(第三次修订草案,743例次)和新方案组(第四次修订方案,499例次),比较AKI发生率和MTX血药浓度。
主要发现
- 新方案组低危患儿AKI发生率1.3%(3/229),低于原方案组7.9%(24/303),χ²=11.831,P<0.05。
- 新方案组中危患儿AKI发生率4.9%(10/204),低于原方案组12.8%(26/203),χ²=7.888,P<0.05。
- 高危患儿AKI发生率两组间差异无统计学意义[15.2%(10/66)比10.5%(25/237),χ²=1.071,P>0.05]。
- 新方案组低危、中危患儿48小时MTX血药浓度及降至安全范围天数均小于原方案组(P均<0.05)。
- 高危患儿上述MTX血药浓度及降至安全范围天数两组间差异均无统计学意义(P均>0.05)。
关键数值与推荐
- 低危患儿48小时MTX血药浓度:新方案组0.36(0.08~4.00)μmol/L,原方案组0.44(0.06~32.00)μmol/L,Z=-5.953,P<0.05。
- 中危患儿48小时MTX血药浓度:新方案组0.49(0.22~33.00)μmol/L,原方案组0.60(0.18~83.00)μmol/L,Z=-2.658,P<0.05。
- 低危患儿MTX降至安全范围天数:新方案组3(2~6)d,原方案组3(2~11)d,Z=-4.490,P<0.05。
- 中危患儿MTX降至安全范围天数:新方案组3(2~11)d,原方案组3(2~19)d,Z=-4.729,P<0.05。
- 高危患儿48小时MTX血药浓度:新方案组0.61(0.14~36.00)μmol/L,原方案组0.71(0.11~68.00)μmol/L,Z=-1.465,P>0.05。
临床怎么用
- 对低危和中危ALL患儿按第四次修订方案行HD-MTX化疗,可降低AKI风险并加速MTX清除。
- 对高危ALL患儿行HD-MTX化疗时,无论采用第三版或第四版方案,均需密切监测肾毒性和MTX血药浓度。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the influence of the 4th revised treatment recommendations in childhood acute lymphoblastic leukemia (ALL) on high dose methotrexate(HD-MTX)-induced nephrotoxicity and MTX blood concentrations. Method: The clinical data from 330 ALL children who received 1 242 courses of HD-MTX therapies from September 2012 to November 2016 was collected. The courses were divided into two groups based on the chemotherapies: original scheme group was treated with the 3rd revised regimen, and new scheme group was treated with the 4th revised regimen. The two groups in acute kidney injury (AKI) and MTX blood concentrations were compared. Result: The incidences of AKI with low risk (LR) and intermediate risk (IR) in new scheme group were significantly lower than those in original scheme group (1.3%(3/229) vs. 7.9%(24/303), 4.9%(10/204) vs. 12.8%(26/203), χ(2)=11.831 and 7.888 respectively, both P<0.05). There was no significant difference in the incidence of AKI with high risk (HR) in the two groups (15.2%(10/66) vs. 10.5%(25/237), χ(2)=1.071, P>0.05). The 48h MTX blood concentrations and the interphase from onste to MTX concentrations decreased to the safe level with LR and IR children in new scheme group were significantly lower than those in original scheme group (0.36(0.08-4.00) vs. 0.44(0.06-32.00) μmol/L, 0.49(0.22-33.00) vs. 0.60(0.18-83.00) μmol/L, 3(2-6) vs. 3(2-11) d, 3(2-11) vs. 3(2-19) d, Z=-5.953, -2.658, -4.490 and -4.729 respectively, all P<0.05). The differences with HR were not observed between the two groups (0.61(0.14-36.00) vs. 0.71(0.11-68.00) μmol/L, 3(2-15) vs. 3(2-13) d, Z=-1.465 and -1.179 respectively, both P>0.05). Conclusion: Decreased renal toxicity and acceleration of MTX excretion may occur when childhood ALL with LR and IR were treated with the 4th revised regimen. However, nephrotoxicity and MTX blood concentrations have no significant differences with HR in the two regimens, and close monitoring are necessary. 目的: 探讨第四次修订的儿童急性淋巴细胞白血病(ALL)诊疗建议实施对大剂量甲氨蝶呤(HD-MTX)化疗后肾毒性及血药浓度影响。 方法: 收集2012年9月至2016年11月330例ALL患儿共1 242例次HD-MTX化疗的临床资料,依据化疗方案分为两组:以"第三次修订草案"化疗为原方案组(743例次),以"第四次修订方案"化疗为新方案组(499例次),比较两组的急性肾损伤(AKI)发生率和MTX血药浓度。 结果: 新方案组的低危和中危患儿的AKI发生率均明显低于原方案组[1.3% (3/229)比7.9% (24/303),4.9% (10/204)比12.8% (26/203),χ(2) =11.831、7.888,P均<0.05],高危患儿的AKI发生率两组间比较差异无统计学意义[15.2% (10/66)比10.5% (25/237),χ(2)=1.071,P>0.05]。新方案组的低危、中危患儿的48 h MTX血药浓度及其降至安全范围的天数均明显小于原方案组[0.36 (0.08~4.00)比0.44 (0.06~32.00)μmol/L,0.49 (0.22~33.00)比0.60 ( 0.18~83.00)μmol/L,3 (2~6)比3 (2~11)d,3 (2~11)比3 (2~19) d,Z=-5.953、-2.658、-4.490、-4.729,P均<0.05],但高危患儿的上述数据两组间比较差异均无统计学意义[0.61 (0.14~36.00)比0.71 (0.11~68.00)μmol/L,3 (2~15)比3 (2~13) d,Z=-1.465、-1.179,P均>0.05]。 结论: 按第四次修订的方案行HD-MTX化疗后,低危和中危患儿的肾毒性发生风险降低,MTX体内清除时间缩短,但高危患儿的肾毒性及MTX血药浓度无明显变化,应注意密切监测。.
引用
- Cheng DH, Lu H, Zou XQ, et al. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition]. Zhonghua Er Ke Za Zhi. 2017. PMID: 29050116. doi:10.3760/cma.j.issn.0578-1310.2017.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。